MedTrace Logo

FRench Elective Oocyte prEservation: a Multicenter Study thrEe Years Later

NCT07138469 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 351

Last updated 2025-08-22

No results posted yet for this study

Summary

Previously reserved for pathological cases, oocyte cryopreservation for non-medical reason also named elective fertility preservation (EFP) is now authorized in France for women aged 29 to 37 following the revision of the bioethics law on August 2nd 2021. Currently, French data related to this new practice are lacking. The aim of this study is to conduct a preliminary assessment 3 years after approval of elective oocyte cryopreservation in France, evaluating the knowledge and perspectives of women undergoing elective fertility preservation in order to gain a better understanding of this new population and define the socio-economic and demographic profiles to improve care quality.

Conditions

  • Elective Fertility Preservation

Interventions

OTHER

Questionnaire

The questionnaire was offered on a voluntary basis and completed online by the participants. At the end of the inclusion period, the responses were analyzed. Participant indicated in the questionnaire whether or not they had already undergone oocyte cryopreservation. The responses were analyzed to assess demographic characteristics, the level of knowledge regarding the bioethics law on non-medical fertility preservation, and future perspectives in the event of use (desired parental model, likelihood of use) or non-use.

Sponsors & Collaborators

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Jeanne Dufaure, MD · University Hospital, Clermont-Ferrand

  • Florence Brugnon, MD,PhD,HDR · University Hospital, Clermont-Ferrand

Eligibility

Min Age
29 Years
Max Age
37 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07138469 on ClinicalTrials.gov